New blood test combined with image-based prostate cancer screening reduces harms and costs

The combination of a novel blood test and magnetic resonance imaging (MRI) can reduce overdiagnosis of low-risk cancers as well as societal costs in prostate cancer screening, according to a cost-effectiveness study. https://www.sciencedaily.com/releases/2022/01/220128100728.htm